Meropenem Stada

Meropenem, the active ingredient in Meropenem Stada, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, meningitis, and sepsis in hospitalized patients.

GNH USA supplies Meropenem Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, ensuring quality‑controlled manufacturing and reliable cold‑chain logistics. The company adheres to EU GMP standards and provides regulatory documentation to support import and clinical use across multiple regions.

Meropenem is a carbapenem antibiotic indicated for serious bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with intra‑abdominal infections requiring broad‑spectrum coverage. Complicated urinary tract infections: provides effective treatment of resistant Gram‑negative uropathogens in complicated UTIs. Nosocomial pneumonia: delivers rapid bacterial clearance in hospital‑acquired lung infections, including ventilator‑associated pneumonia. Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible organisms. Severe sepsis and septic shock: supports hemodynamic stabilization by controlling the underlying infection in critically ill patients.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: skin erythema or pruritus. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Seizures: risk heightened in patients with renal impairment or pre‑existing CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Neutropenia or thrombocytopenia: reductions in white blood cells or platelets that may require monitoring.

When using Meropenem, clinicians should observe several safety considerations to minimize risk.

Renal function: assess creatinine clearance and adjust dose in renal impairment. Hepatic function: monitor liver enzymes during prolonged therapy. Seizure risk: use cautiously in patients with a history of seizures or CNS disorders. Allergic history: verify absence of severe β‑lactam allergy before administration. Pregnancy and lactation: weigh potential benefits against unknown risks; use only if clearly needed. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Valproic acid: co‑administration markedly reduces valproate levels, increasing seizure risk. - Probenecid: may increase meropenem plasma concentrations, raising toxicity potential. - Aminoglycosides: concurrent use can enhance nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect renal clearance; monitor renal function. - Warfarin: meropenem may potentiate anticoagulant effect; check INR. - NSAIDs: combined renal stress; observe kidney function. - Other β‑lactam antibiotics: possible antagonism; avoid simultaneous use unless clinically justified.